High fasting blood glucose tied to increased CRC risk in patients without diabetes

Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.

Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.

Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.